Condition: Lung Cancer · COPD · Emphysema · Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación Jiménez Díaz University Hospital and Villalba General Hospital, in Madrid, Spain. The aim of this observational study is to determine the scientific evidence needed to study the benefit and potential effects of lung cancer screening in this group of patients and to determine the long-term effects of the intervention in reducing the high mortality rates associated with late-stage lung cancer diagnosis in a very high-risk population, to address under-diagnosis of COPD and to promote smoking cessation. This leads to the creation of a registry with clinical, radiological, functional data and biological samples for future studies in this cohort of patients to provide the scientific evidence needed to study the benefit and potential effects of screening for lung cancer and other tobacco-related pathologies diagnosed by Low-dose CT (LDCT)
This description comes directly from the study's public registry record.
Carolina Gotera, MD · +34 915504800 · carolina.gotera@fjd.es
María Jesús Rodríguez Nieto, MD phD · +34 915504800 · mjrodriguezn@fjd.es
Always discuss trial participation with your own doctor first.
| Fundación Jimenez Díaz Universitary Hospital | Madrid, Spain | Recruiting |
| Pneumology department. Fundación Jimenez Díaz University Hospital | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06690385